In an interview with Pharmacy Times, Michael Snyder, MD, FACS, FASMBS, in-house obesity specialist at FuturHealth and medical director of the Bariatric Surgery Center at Rose Medical Center, addressed the growing patient safety concerns surrounding compounded glucagon-like peptide-1 (GLP-1) medications, arguing that the FDA's recent regulatory actions reflect a necessary effort to rein in a market where demand has outpaced oversight.
Snyder emphasized that claims by compounding pharmacies and telehealth platforms that their products are "equivalent to" FDA-approved semaglutide (Ozempic, Wegovy; Novo Nordisk) or tirzepatide (Mounjaro, Tirzepatide; Eli Lilly and Company) are pharmacologically and clinically misleading, as even minor differences in formulation, sourcing, or manufacturing can lead to dose variability, impurities, inconsistent absorption, and unpredictable adverse effects. Snyder outlined key red flags pharmacists should watch for, including unusually low pricing, vague labeling, nonstandard dosing instructions, and patients who report never having undergone a formal clinical intake or contraindication screening.
He also stressed that GLP-1 medications are powerful endocrine therapies that require clinical monitoring, thoughtful titration, and comprehensive support around nutrition, hydration, and long-term metabolic health to be used safely and effectively.
Pharmacy Times: From your perspective, what does the FDA’s regulatory action against unauthorized GLP-1 medications signal about patient safety concerns with these compounded formulations?
Snyder: This action signals that the FDA is prioritizing patient safety amid a rapidly expanding market where demand has outpaced guardrails. When products are being marketed outside of FDA approval—especially with aggressive, consumer-facing claims—there’s real concern about quality, consistency, and misleading expectations.
The FDA’s actions underscore that “GLP-1” is not a generic category label; it’s a class of prescription therapies where the details of formulation, dosing accuracy, and manufacturing standards matter. Simply put, “the science matters.” Patients’ expectations of results and safety are related to the hard work that the pharmacy companies have done to create safe and effective medications. Any shortcuts are both unproven and not in line with the trial-proven clinical realities.
Key Takeaways
- "Equivalent" does not mean the same thing. Compounded GLP-1 products cannot be assumed to match FDA-approved medications in purity, stability, dosing accuracy, or clinical performance — and pharmacists should help patients understand that distinction clearly.
- Know the red flags. Unusually low pricing, vague labeling, non-standard titration instructions, and patients reporting no formal clinical intake or prescriber access are all warning signs that a GLP-1 product or program may not meet safety standards.
- GLP-1s require a structured care model, not a transactional one. Safe, sustainable outcomes depend on verified medication sourcing, licensed clinicians, ongoing monitoring, and behavioral and nutritional support — medication alone is not sufficient.
Pharmacy Times: Some compounding pharmacies and telehealth platforms have marketed their products as being "equivalent to" or "the same as" FDA-approved semaglutide and tirzepatide. Can you explain why these claims are problematic from both a pharmacological and clinical standpoint?
Snyder: Those claims are problematic because “equivalent” implies equality all around: the same active ingredient, the same purity, the same stability, the same delivery characteristics, and the same clinical performance—none of which can be assumed without FDA review.
Even small differences in formulation, sourcing, or manufacturing can change how a drug is absorbed, tolerated, and dosed. Clinically, that can translate into unpredictable [adverse] effects, variable appetite suppression, and inconsistent results, which makes it harder to manage patients safely and effectively. Despite common misconceptions, it is not “getting a cheaper version of the same drug.” In reality, it is getting an unproven version of a drug that may be similar—in no way is it the same thing.
Pharmacy Times: What specific risks do patients face when using compounded GLP-1 products that lack the rigorous testing, quality controls, and postmarket surveillance required of FDA-approved medications?
Snyder: The major risks are potential dose variability, impurities/contamination, sterility concerns (particularly with injectables), differences in absorption and/or delivery, and inconsistent clinical response. Patients may also lack appropriate screening for contraindications and may not have a clear path for monitoring, titration, or [adverse] effect management. And without the same postmarket surveillance infrastructure, safety signals can be harder to detect and address at scale.
Pharmacy Times: Pharmacists are often the last health care touchpoint before a patient begins GLP-1 therapy. What red flags should pharmacists watch for when patients present prescriptions from online or direct-to-consumer weight management services?
Snyder: Key red flags include unusually low pricing that seems disconnected from legitimate supply chains; vague labeling or unclear ingredient sourcing; dosing instructions that don’t align with standard titration practices; lack of documentation around baseline labs or contraindication screening; and patients reporting that they never had a real clinical intake, follow-up plan, or access to a prescriber for [adverse] effects. Another concern is when patients describe being told the product is “the same as” an FDA-approved drug without clear evidence or transparency.
Pharmacy Times: As access to GLP-1 medications expands and marketing from various providers intensifies, what criteria should consumers—and the pharmacists counseling them—prioritize when evaluating the safety and legitimacy of a GLP-1 prescriber or program?
GLP-1 medications can be transformative when used appropriately. But they are powerful endocrine therapies—not lifestyle supplements—and they deserve to be treated with that level of seriousness. - Michael Snyder, MD, FACS, FASMBS
Snyder: They should prioritize FDA-approved medications dispensed through regulated pharmacies, care delivered by licensed clinicians, and a clearly defined monitoring plan. That includes eligibility screening, contraindication review, structured titration, and ongoing follow-up.
It’s also important that the program doesn’t treat GLP-1s as a standalone solution. Obesity is a chronic metabolic disease, and outcomes improve when medication is paired with nutrition guidance, hydration planning, muscle preservation strategies, and behavioral support. In structured, physician-guided models like FuturHealth, medication is integrated into a broader care plan rather than dispensed transactionally, and that distinction has real safety implications.
Pharmacy Times: Looking ahead, how do you anticipate the regulatory and clinical landscape for GLP-1 access will evolve, and what should pharmacists prepare for as gatekeepers of medication safety?
Snyder: I expect continued regulatory clarification around marketing claims and compounded products, along with more emphasis on transparency in sourcing and formulation. Clinically, we’ll likely see expanded formats, refined dosing options, and broader adoption, but also higher expectations for medical oversight.
Pharmacists should prepare for more patient questions driven by online advertising and social media. They’ll play an increasingly important role in helping patients distinguish between FDA-approved therapies dispensed through legitimate care models and products marketed in ways that blur those lines.
As programs like FuturHealth’s demonstrate, the future of GLP-1 care isn’t just about access—it’s about integration. Medication needs to sit within a longitudinal care structure that includes clinical monitoring, dietary strategy, and [adverse] effect management. That’s where safety and sustainability intersect.
Pharmacy Times: Is there anything else that you would like to add?
Snyder: GLP-1 medications can be transformative when used appropriately. But they are powerful endocrine therapies—not lifestyle supplements—and they deserve to be treated with that level of seriousness. “Shortcuts” may look appealing in a high-demand market, but structured, regulated care is what protects patients in the long run.
The most important safeguard is structure: verified medication sourcing, licensed clinicians, thoughtful titration, and ongoing support around nutrition, hydration, and long-term metabolic planning. Safely and effectively using such powerful and revolutionary medications should be a part of a much larger patient management plan, inclusive of dietary and behavioral modification and long-term medical oversight. Anything less may well prove to be ineffective (at best) and dangerous (at worst). At FuturHealth, we view medication as one component of a comprehensive care model, because the goal isn’t just short-term weight loss; it’s durable metabolic health achieved safely.
